AHA's feedback on a Drug Enforcement Administration proposed rule for the telemedicine prescribing of controlled substances when there has not been a prior in-person medical evaluation.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA provides feedback on the Drug Enforcement Administration’s (DEA’s) proposed rule for expansion of induction of buprenorphine via telemedicine encounter.
AHA comments on the FDA's draft guidance proposing that blood donor eligibility be determined based on individual risk assessment, regardless of gender or sexual orientation.
March 29, 2023
The AHA writes to express support for the Rural America Health Corps Act (S.940).
AHA provides information for hearing on “Why Health Care is Unaffordable: The Fallout of Democrats’ Inflation on Patients and Small Businesses.”
AHA, health organizations request increased funding for Children's Hospitals Graduate Medical Education Program.
AHA comments on the proposed Standards for Health Care Attachments Transactions and Electronic Signatures, and Modification to Referral Certification and Authorization Transaction Standard.
AHA responds to the RFI on the drivers of health care workforce shortages and solutions.
AHA comments on the Request for Information on the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).